TNF and ankylosing spondylitis: The decrease in ferroptosis and lipid ROS levels induced by TNF could be eliminated by adalimumab, a fully human monoclonal TNF antibody (Fig. 5e, f) that has been approved for the treatment of RA, juvenile idiopathic arthritis, ankylosing spondylitis, and inflammatory bowel disease27.